Quinupristin-dalfopristin: an overview (Q34113774)

31 July 2017

1 reference

title

Quinupristin-dalfopristin: an overview (English)

1 reference

31 July 2017

Delgado G Jr

1

1 reference

31 July 2017

Neuhauser MM

series ordinal

2

1 reference

31 July 2017

Bearden DT

series ordinal

3

1 reference

31 July 2017

Danziger LH

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

20

1 reference

31 July 2017

12

1 reference

31 July 2017

1469-1485

1 reference

Inhibition of protein synthesis by streptogramins and related antibiotics

31 July 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

In-vitro activity of ten antimicrobial agents against penicillin-resistant Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Post-antibiotic effect of the new streptogramin RP 59500.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

A variety of gram-positive bacteria carry mobile mef genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Safety and tolerability of quinupristin/dalfopristin: administration guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Gram-positive infections: pharmacy issues and strategy for quinupristin/dalfopristin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.19.1469.34858

10.1592/PHCO.20.19.1469.34858

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference